Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

P3 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Knee or Hip Replacement Surgery

NCT01660763 is registered in ClinicalTrials.gov with Talphera, Inc as lead sponsor.

NCT NCT01660763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01660763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
P3 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Knee or Hip Replacement Surgery
Lead sponsor
Talphera, Inc
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2012
Completion date
May 31, 2013
Enrollment
419 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

post operative pain